PeppiLibrary

Healing

Larazotide peptide reference

Octapeptide tight-junction modulator. Researched for celiac disease and leaky gut.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Larazotide notes
Default dose label500 mcg
Preferred routeOral
Frequency labelUp to 3× daily before meals
Storage windowNot listed

Evidence snapshot

Human data

Evidence maturityHuman data
Phase 3 completed — failed primary endpoint in CeDLara trial

Investigational / research chemical

Route map

How records are usually labeled

1 Oral

N/A — systemic oral.

Vial timeline

Storage cues to log

Before mixRoom temperature, dry place.
After mixN/A
Use-by cueShelf life not listed
Mixed vial windowNot listed
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial label
Dose 500 mcg
Route Oral
Review storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Larazotide. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Larazotide is a synthetic 8-amino-acid peptide that modulates zonulin signalling and helps maintain intestinal tight junctions. It has been studied as an adjunct in celiac disease to reduce gluten-triggered intestinal permeability ('leaky gut') and downstream symptoms. Phase 3 trial (CeDLara) failed its primary endpoint in 2022; development for celiac was discontinued, but research interest in tight-junction modulation continues.

Also known as: AT-1001, INN-202.

Celiac disease adjunct (failed Phase 3 endpoint)Intestinal permeability researchLeaky-gut protocols (research)

Mechanism and timing snapshot

Antagonises zonulin-mediated tight-junction disassembly. Acts locally in the GI lumen — minimal systemic absorption is intentional and desirable.

Onset labelNot listed
Catalog onset field, when available.
Half-life label1 hr
Locally active in gut lumen; minimal systemic exposure
Duration label6 hr
Catalog duration field, when available.
oral Locally active in gut; systemic absorption <1% (intentional)

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose500 mcg
Catalog dose range250 mcg - 1 mg
Default routeOral
Frequency labelUp to 3× daily before meals
Best time label15 min before meals containing gluten or trigger foods.
Food noteTake before meals; food intake during the activity window is the point.

Catalog protocol note

0.5 mg orally 15 min before each meal, 3× daily (clinical trial protocol).

Routes and site notes

Available route labelsOral
Preferred route labelOral
Common site labelsGI tract
Site rotation noteN/A — systemic oral.

Chemistry

SequenceGly-Gly-Val-Leu-Val-Gln-Pro-Gly
Amino acids8
Molecular formulaC32H55N9O10
Molecular weight725.84 Da

Vial, reconstitution, and storage

Supply formCapsule or powder for oral use
Typical vial sizeNot listed
DiluentN/A — oral
Diluent volumeNot listed
Concentration notePre-dosed capsules (typically 0.5 mg) in clinical trial form.
Before reconstitutionRoom temperature, dry place.
After reconstitutionN/A
Reconstituted shelf lifeNot listed
Light sensitiveNo
Freeze/thaw warningNo

Safety notes

Common and rare side effects listed in the catalog

  • Generally extremely well-tolerated
  • Headache (occasional)
  • Mild GI upset

Contraindications and warnings

  • Pregnancy (limited data)
  • Phase 3 failed its primary endpoint (2022); not approved.

Other considerations

  • Designed for local gut activity — minimal systemic effect by design.
  • Failed Phase 3 means clinical efficacy in celiac is unproven.
  • Mechanism (tight-junction stabilisation) remains scientifically interesting.

Evidence and regulatory context

Evidence levelPhase 3 completed — failed primary endpoint in CeDLara trial
FDA approvedNo
Regulatory statusInvestigational / research chemical
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withbpc-157, kpv
Avoid combining noteNot listed
Typical cycle labelongoing during trigger exposure
Typical break labelN/A
Cycle guidanceUsed before each meal containing trigger foods; not a chronic supplement.

Tracking tips

  • Best taken 15 min before meals to be in the gut when gluten/triggers arrive.
  • Phase 3 endpoint failure tempers expectations for celiac use.
  • Pairs with BPC-157 and KPV in gut-healing research stacks.

References

Track it in Peppi

Keep Larazotide records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Larazotide?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Larazotide?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Larazotide records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026